Clinical Trial Update: Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-PD-1 antibody plus P-GEMOX chemotherapy with radiotherapy for high-risk, early-stage Extranodal NK/T-Cell Lymphoma, nasal type.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Extranodal Nk-t-cell Lymphoma Nasal and Nasal-type

Drugs mentioned

• Anti-PD-1 antibody
• P-GEMOX chemotherapy

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage | Phase 2 | Status: UNKNOWN